Correction: Kuypers et al. Evaluation of Neonatal Screening Programs for Tyrosinemia Type 1 Worldwide. Int. J. Neonatal Screen. 2024, 10, 82

The authors wish to make the following correction to their paper published in the International Journal of Neonatal Screening [1].

1. In the Abstract, overall positive predictive values for SUAC should be 25.9% instead of 27.3%;

2. In the Introduction, the sentence “Moreover, since the start of SUAC NBS for TT1 in the Netherlands, 57% of positive screening results have proven to be FP results, and in 2020, a false-negative (FN) TT1 patient emerged” should be updated to “Moreover, since the start of SUAC NBS for TT1 in the Netherlands, 82% of positive screening results have proven to be FP results, and in 2020, a false-negative (FN) TT1 patient emerged”;

3. In Table 1, the TP of the Netherlands should be 11 instead of 27, the incidence (study period) should be 1/214,437 instead of 1/87,363, the FP results should be 49 instead of 35, the FP rate (incidence) should be 1/48,139 instead of 1/67,395, and the PPV (%) should be 18.3% instead of 43.4%;

4. The authors would like to replace Figure 2 with the following figure; only the FP rate of the Netherlands was changed from 1/67,395 to 1/48,139;

5. In Section 3.2.6, the sentence “Combined, they reported 304 TP results and 811 FP results, yielding a combined PPV for SUAC TT1 screening of 27.3%. Combined, all programs screening with Tyr as the primary marker and SUAC as the secondary marker screened 5,273,431 children” should be updated to “Combined, they reported 288 TP results and 825 FP results, yielding a combined PPV for SUAC TT1 screening of 25.9%. Combined, all programs screening with Tyr as the primary marker and SUAC as the secondary marker screened 5,273,431 children”;

6. In Section 3.2.7, the sentence “a FP-rate of 1:83,310 for the NeoBase™ Non-derivatized MSMS kit from Revvity in programs using SUAC as sole marker, and a FP-rate of 1:127,531 for the NeoBase™ 2 non-derivatized MSMS kit from Revvity in programs using SUAC as sole marker” should be updated to “a FP-rate of 1:83,310 for the NeoBase™ Non-derivatized MSMS kit from Revvity in programs using SUAC as sole marker, and a FP-rate of 1:103,058 for the NeoBase™ 2 non-derivatized MSMS kit from Revvity in programs using SUAC as sole marker”;

7. In the Discussion, the sentence “In our study, 15 out of 36 (41.7%) NBS programs using SUAC had a PPV < 60%, and the combined PPV of all programs screening with SUAC as the primary marker was 27.3%” should be updated to “In our study, 15 out of 36 (41.7%) NBS programs using SUAC had a PPV < 60%, and the combined PPV of all programs screening with SUAC as the primary marker was 25.9%”;

8. In the backmatter section, the Institutional Review Board Statement should be updated to “Institutional Review Board Statement: The Institutional Review Board Statement was waived because this study did not include clinical research with individual human subjects as meant by the Dutch Medical Research Act involving human subjects”. The Informed Consent Statement should be updated to “Informed Consent Statement: The Informed Consent Statement was waived because this study did not include clinical research with individual human subjects as meant by the Dutch Medical Research Act involving human subjects”.

We would like to apologize for any inconvenience caused to the readers by these changes. The changes do not affect the scientific results. This correction was approved by the Academic Editor. The original publication has also been updated.